[HTML][HTML] Prevalence of glucose-6-phosphate dehydrogenase deficiency (G6PDd), CareStart qualitative rapid diagnostic test performance, and genetic variants in two …

MM Ali Albsheer, AA Lover, SB Eltom… - PLoS Neglected …, 2021 - journals.plos.org
Glucose-6-phosphate dehydrogenase deficiency (G6PDd) is the most common
enzymopathy globally, and deficient individuals may experience severe hemolysis following …

[HTML][HTML] Assessment of glucose-6-phosphate dehydrogenase activity using CareStart G6PD rapid diagnostic test and associated genetic variants in Plasmodium vivax …

OKM Djigo, MA Bollahi, M Hasni Ebou… - PLoS …, 2019 - journals.plos.org
Background Primaquine is recommended by the World Health Organization (WHO) for
radical treatment of Plasmodium vivax malaria. This drug is known to provoke acute …

[HTML][HTML] Screening for glucose-6-phosphate dehydrogenase deficiency using three detection methods: a cross-sectional survey in southwestern Uganda

ME Roh, C Oyet, P Orikiriza, M Wade… - The American journal …, 2016 - ncbi.nlm.nih.gov
Despite the potential benefit of primaquine in reducing Plasmodium falciparum transmission
and radical cure of Plasmodium vivax and Plasmodium ovale infections, concerns over risk …

[HTML][HTML] Prevalence and molecular basis of glucose-6-phosphate dehydrogenase deficiency in Afghan populations: implications for treatment policy in the region

T Leslie, B Moiz, N Mohammad, O Amanzai… - Malaria journal, 2013 - Springer
Background Glucose-6-phosphate dehydrogenase deficiency (G6PD), an x-linked inherited
enzymopathy, is a barrier to malaria control because primaquine cannot be readily applied …

[HTML][HTML] Barriers to routine G6PD testing prior to treatment with primaquine

B Ley, K Thriemer, J Jaswal, E Poirot, MS Alam… - Malaria journal, 2017 - Springer
Background Primaquine is essential for the radical cure of vivax malaria, however its broad
application is hindered by the risk of drug-induced haemolysis in individuals with glucose-6 …

[HTML][HTML] Performance of a commercial multiplex allele-specific polymerase chain reaction kit to genotype African-type glucose-6-phosphate dehydrogenase deficiency

OKM Djigo, N Gomez, MSOA Salem… - The American Journal …, 2023 - ncbi.nlm.nih.gov
8-Aminoquinoline antimalarial drugs (primaquine, tafenoquine) are required for complete
cure of Plasmodium vivax malaria, but they are contraindicated in patients with glucose-6 …

[HTML][HTML] Glucose-6-phosphate dehydrogenase deficiency among malaria suspects attending Gambella hospital, southwest Ethiopia

A Tsegaye, L Golassa, H Mamo, B Erko - Malaria journal, 2014 - Springer
Background Glucose-6-phosphate dehydrogenase deficiency (G6PDd) is widespread
across malaria endemic regions. G6PD-deficient individuals are at risk of haemolysis when …

Assessment of CareStart G6PD rapid diagnostic test and CareStart G6PD biosensor in Mauritania

OKM Djigo, YO Khalef, MSOA Salem… - Infectious Diseases of …, 2021 - mednexus.org
Background: The elimination of Plasmodium vivax malaria requires 8-aminoquinolines,
which are contraindicated in patients with glucose-6-phosphate dehydrogenase (G6PD) …

[HTML][HTML] Validation of G6PD point-of-care tests among healthy volunteers in Yangon, Myanmar

NN Oo, G Bancone, LZ Maw, N Chowwiwat, P Bansil… - PloS one, 2016 - journals.plos.org
Primaquine and other 8-amnoquinoline based anti-malarials can cause haemolysis in
subjects with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Correct diagnosis of …

[HTML][HTML] Frequency of glucose-6-phosphate dehydrogenase deficiency in malaria patients from six African countries enrolled in two randomized anti-malarial clinical …

N Carter, A Pamba, S Duparc, JN Waitumbi - Malaria journal, 2011 - Springer
Abstract Background Glucose-6-phosphate dehydrogenase (G6PD) deficiency is common in
populations living in malaria endemic areas. G6PD genotype and phenotype were …